JP2024529875A5 - - Google Patents

Info

Publication number
JP2024529875A5
JP2024529875A5 JP2024501734A JP2024501734A JP2024529875A5 JP 2024529875 A5 JP2024529875 A5 JP 2024529875A5 JP 2024501734 A JP2024501734 A JP 2024501734A JP 2024501734 A JP2024501734 A JP 2024501734A JP 2024529875 A5 JP2024529875 A5 JP 2024529875A5
Authority
JP
Japan
Prior art keywords
rna
dux4
administration
manipulated
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024501734A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529875A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/073754 external-priority patent/WO2023288289A2/en
Publication of JP2024529875A publication Critical patent/JP2024529875A/ja
Publication of JP2024529875A5 publication Critical patent/JP2024529875A5/ja
Pending legal-status Critical Current

Links

JP2024501734A 2021-07-14 2022-07-14 神経筋障害のためのオリゴヌクレオチドおよびその組成物 Pending JP2024529875A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163221568P 2021-07-14 2021-07-14
US63/221,568 2021-07-14
PCT/US2022/073754 WO2023288289A2 (en) 2021-07-14 2022-07-14 Oligonucleotides and compositions thereof for neuromuscular disorders

Publications (2)

Publication Number Publication Date
JP2024529875A JP2024529875A (ja) 2024-08-14
JP2024529875A5 true JP2024529875A5 (https=) 2025-07-22

Family

ID=83188125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024501734A Pending JP2024529875A (ja) 2021-07-14 2022-07-14 神経筋障害のためのオリゴヌクレオチドおよびその組成物

Country Status (11)

Country Link
US (1) US20240271134A1 (https=)
EP (1) EP4370678A2 (https=)
JP (1) JP2024529875A (https=)
KR (1) KR20240032998A (https=)
CN (1) CN117677698A (https=)
AU (1) AU2022312501A1 (https=)
CA (1) CA3223876A1 (https=)
CO (1) CO2024000116A2 (https=)
IL (1) IL310063A (https=)
MX (1) MX2024000754A (https=)
WO (1) WO2023288289A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021188390A1 (en) 2020-03-19 2021-09-23 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
CN118265544A (zh) 2021-09-16 2024-06-28 艾维迪提生物科学公司 治疗面肩肱型肌营养不良的组合物和方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
EP2736539B1 (en) * 2011-07-25 2017-08-23 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of dux4
WO2017007886A2 (en) * 2015-07-08 2017-01-12 Idera Pharmaceuticals, Inc. Compositions for inhibiting dux4 gene expression and uses thereof
KR20230023612A (ko) * 2020-04-02 2023-02-17 마이레큘, 인크. 조작된 올리고뉴클레오티드를 사용한 표적화된 억제
US20240336915A1 (en) * 2021-01-22 2024-10-10 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing dux4 expression

Similar Documents

Publication Publication Date Title
US11920132B2 (en) Oligonucleotide therapy for Leber congenital amaurosis
CN110636866B (zh) 用于肌肉萎缩症的外显子跳跃寡聚体缀合物
US20180073024A1 (en) Chimeric double-stranded nucleic acid
CN112384222B (zh) 用于肌营养不良的外显子跳跃寡聚物缀合物
CN109072238B (zh) 使用靶向结缔组织生长因子的rna复合物治疗特发性肺纤维化
CN108136206A (zh) 抗乙型肝炎病毒的组合物和药剂及其用途
JP2024529875A5 (https=)
JP2023506540A (ja) B型肝炎ウイルス感染を処置するためのscamp3阻害剤の使用
CN113412330A (zh) 用于肌营养不良的外显子跳跃寡聚物缀合物
CN102028947B (zh) Fam3b基因的抑制剂和组合物及抑制方法以及脂肪肝的疗法和抑制剂的制药用途
KR20250120382A (ko) 유전자 침묵 기술로서 산재된 데옥시리보뉴클레오타이드를 갖는 짧은 이중체 rna 및 이의 용도
JP2025504474A5 (https=)
CN118369428A (zh) 作为新型基因沉默技术的短双链体dna及其应用
CN115698290A (zh) 用于治疗神经系统疾病的补体组分4抑制剂以及使用它们的相关组合物、系统和方法
JP2023527684A (ja) 神経疾患を治療するための補体成分c1s阻害剤、並びにそれを使用する関連組成物、システム及び方法
JP2023506547A (ja) B型肝炎ウイルス感染を処置するためのcops3阻害剤の使用
JP2023506550A (ja) B型肝炎ウイルス感染症を処置するためのsbds阻害剤の使用
CN118512601B (zh) 双链核酸-半乳糖胺-胆固醇化合物及其应用
TW202606722A (zh) iRNA組合物及其使用方法
EP4630009A1 (en) Antisense rna (asrna) technology and use thereof
CN121175422A (zh) 修饰的双链寡核苷酸及其缀合物和组合物
CN121889505A (zh) 抑制actriib表达的寡核苷酸分子及其用途
WO2026077086A1 (zh) 修饰的双链寡核苷酸及其缀合物和组合物
WO2025252184A1 (en) iRNA COMPOSITION AND METHOD OF USING SAME
CN119410644A (zh) 修饰的双链寡核苷酸及其缀合物和组合物